… to treatment with sunitinib. This patient had clear-cell RCC metastatic to the mediastinum
and lung with symptoms of episodic dyspnea. Following 28 days of sunitinib therapy, the …

… The association between adverse events and sunitinib therapy was assessed by the
investigator. Patients who discontinued therapy because of an adverse event continued follow-up …

… of the era of targeted therapy, and specifically the approval of sunitinib, it is worthwhile to …
to the study of sunitinib. We present the key trials and data for sunitinib that established it as a …

… of sunitinib. Fatigue may be partly related to the development of hypothyroidism during sunitinib
therapy … Hypertension can be treated with standard antihypertensive therapy and rarely …

… We enrolled 750 patients with previously untreated, metastatic renal-cell carcinoma in a
multicenter, randomized, phase 3 trial to receive either repeated 6-week cycles of sunitinib (at a …

… with histologically confirmed renal cell carcinoma. All renal cell carcinoma patients were
screened for … toxicity after receiving either sorafenib or sunitinib, and then these patients were …

… therapy with sunitinib in patients with metastatic RCC. The tumor response and durability of
response to sunitinib … As second line therapy, the sunitinib response rate was 2 to 3 times …

… Sunitinib is an oral tyrosine kinase inhibitor which interferes … sunitinib therapy with emphasis
on establishing effective patient education for anticipation and early management of therapy-…

… therapies introduced since 2006, sunitinib has carved its way to become the most commonly
used first-line therapy for the treatment of metastatic renal cell carcinoma (… to sunitinib and …

… sunitinib in mRCC, with an emphasis on real-world data, and utilize clinical case studies to
examine the successful implementation of therapy … effects associated with sunitinib therapy, …